在接受恩替卡韦或替诺福韦的亚洲慢性乙型肝炎患者中验证PA

StephenW

VIRAL HEPATITIS
Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir

    Mi Na Kim1, Seong Gyu Hwang1, Kyu Sung Rim1, Beom Kyung Kim2, Jun Yong Park2, Do Young Kim2, Sang Hoon Ahn2, Kwang-Hyub Han2 andSeung Up Kim2,*

Version of Record online: 12 MAY 2017

DOI: 10.1111/liv.13450

© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Issue
Liver International

Volume 37, Issue 12, pages 1788–1795, December 2017

    1    Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea
    2    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Email: Seung Up Kim ([email protected])

* Correspondence
Seung Up Kim, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Email: [email protected]

    Funding information

    This study was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2016R1A1A1A05005138), and the Ministry of Education, (2015R1D1A1A01058653). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

    Handling Editor: Chun-Jen Liu


Keywords:

    chronic hepatitis B;hepatocellular carcinomaAGE-B;risk prediction model

Abstract
Background & Aims

A new hepatocellular carcinoma risk prediction model, PAGE-B, which includes age, gender and platelet count as constituent variables, has recently been proposed in Caucasian chronic hepatitis B patients. We validated PAGE-B model and compared its accuracy with that of conventional risk prediction models in Asian chronic hepatitis B patients.
Methods

Chronic hepatitis B patients treated with entecavir or tenofovir were consecutively recruited. The performance of PAGE-B and three conventional risk prediction models (CU-HCC, GAG-HCC and REACH-B) were analysed.
Results

A total of 1092 chronic hepatitis B patients (668 men, 61.2%) were selected between August 2006 and January 2015. The mean age was 48 years. During the follow-up period (median, 43.6 months), 36 (3.3%) patients developed hepatocellular carcinoma. Older age (hazard ratio [HR]=1.077), male gender (HR=3.676) and lower platelet count (HR=0.984) were independent predictors of hepatocellular carcinoma development. The PAGE-B showed similar area under receiver operating characteristic curves (AUROCs) to GAG-HCC and CU-HCC at 3 years (0.777 vs 0.793 and 0.743, respectively; all P>.05) and 5 years (0.799 vs 0.803 and 0.744, respectively; all P>.05), whereas the AUROCs of PAGE-B were significantly higher than those of the REACH-B (0.602 at 3 years and 0.572 at 5 years, P<.05).
Conclusions

Our study demonstrated that PAGE-B is applicable to Asian chronic hepatitis B patients receiving ETV or TDF therapy. The PAGE-B showed similar predictive performance to GAG-HCC and CU-HCC.

StephenW

病毒性肝炎
在接受恩替卡韦或替诺福韦的亚洲慢性乙型肝炎患者中验证PAGE-B模型

在线记录版本：2017年5月12日

DOI：10.1111 / liv.13450

©2017 John Wiley＆Sons A / S。 John Wiley＆Sons Ltd出版

问题
肝脏国际

2017年12月，卷37，第12期，第1788-1795页

    1韩国城南CHA大学盆唐医学中心内科
    2韩国首尔延世大学医学院内科

电子邮件：Seung Up Kim（[email protected]）

*通信
韩国首尔延世大学医学院内科医学博士Kim Seung Up博士。
电子邮箱：[email protected]

    资金信息

    本研究由韩国科学，信息通信技术和未来规划（2016R1A1A1A05005138）和教育部资助的韩国国家研究基金（2015R1D1A1A01058653）资助基础科学研究计划。资助者在研究设计，数据收集和分析，决定发表或准备稿件方面没有任何作用

    处理编辑：刘春仁


关键词：

    慢性乙型肝炎;肝细胞癌; PAGE-B;风险预测模型

抽象
背景和目的

最近在高加索慢性乙型肝炎患者中提出了包括年龄，性别和血小板计数作为组成变量的新的肝细胞癌风险预测模型PAGE-B。我们验证了PAGE-B模型，并将其与亚洲慢性乙型肝炎患者的常规风险预测模型的准确性进行了比较。
方法

慢性乙型肝炎患者恩替卡韦或替诺福韦治疗连续招募。分析了PAGE-B和三种常规风险预测模型（CU-HCC，GAG-HCC和REACH-B）的性能。
结果

2006年8月至2015年1月，共有1092名慢性乙型肝炎患者（668名男性，61.2％）被选中，平均年龄为48岁。在随访期间（中位数为43.6个月），36例（3.3％）患者发生肝细胞癌。年龄较大（危险比[HR] = 1.077），男性（HR = 3.676）和血小板计数（HR = 0.984）是肝癌发生的独立预测因子。 PAGE-B显示3年时对GAG-HCC和CU-HCC的受试者工作特征曲线（AUROC）的相似面积（0.777对0.793和0.743，分别为P> 0.05）和5年（0.799对0.803和0.744 ，P> 0.05），而PAGE-B的AUROCs显着高于REACH-B（3年0.602和5年0.572，P <0.05）。
结论

我们的研究表明，PAGE-B适用于接受ETV或TDF治疗的亚洲慢性乙型肝炎患者。 PAGE-B显示与GAG-HCC和CU-HCC相似的预测性能。